Chang Xiaofeng,Wang Huanmin,Wang Jiarong,et al.Application of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for locally recurrent Wilms tumor[J].Journal of Clinical Pediatric Surgery,,():464-468.[doi:10.3760/cma.j.cn101785-202203047-012]
Click Copy

Application of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for locally recurrent Wilms tumor

Journal of Clinical Pediatric Surgery[ISSN:1671-6353/CN:43-1380/R] volume: Number: 2024 No.05 Page: 464-468 Column: 论著 Date of publication: 2024-05-01
Author(s):
Chang Xiaofeng1;  Wang Huanmin1;  Wang Jiarong2;  Meng Deguang2;  Qin Hong1;  Yang Wei1;  Cheng Haiyan1;  Zhu Zhiyun1
1 Department of Surgical Oncology, Beijing Children’s Hospital Affiliated to Capital Medical University, Beijing 100045, China;
2 Department of Oncology, Baoding Hospital, Beijing Children’s Hospital, Baoding 071000, China
Keywords:
Cytoreductive Surgery; Hyperthermic Intraperitoneal Chemotherapy; Wilms Tumor; Surgical Procedures;  Operative; Child
DOI:
10.3760/cma.j.cn101785-202203047-012
Abstract:
Objective To evaluate the efficacy of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for locally recurrent nephroblastoma.Methods For this retrospective study,six children with locally recurrent nephroblastoma were recruited from January 2019 to January 2022.Personal demographics (gender,age & disease site),previous protocols,treatment plans,surgical procedures,HIPEC,postoperative management and follow-ups were collected.Results All of them had unilateral lesions.Radical nephrectomy (n=5) and nephron sparing surgery (NSS,n=1) were performed.Two cases of Children’s Oncology Group (COG) stage Ⅲ received chemoradiotherapy while another two of stage Ⅱ had chemotherapy alone.The remainders received preoperative chemotherapy and postoperative International Society of Pediatric Oncology (SIOP) stage was both stage Ⅱ.The shortest time to recurrence was 1.5 months while the longest one 10 months.All abdominopelvic lesions were removed without distant metastases.Five cases received local radiotherapy and intensive postoperative chemotherapy.CRS plus HIPEC were offered without any perioperative life-threatening complication.The median follow-up period was 14(2-32) months).The outcomes were long-term survival (n=4) and tumor progression (n=2).Conclusions The prognosis for locally recurrent nephroblastoma remains unsatifactory.However,with an aid of adjunctive chemotherapy,CRS plus HIPEC are capable of maximizing the eradication of residual tumor cells and thus facilitating local tumor control.

References:

[1] Irtan S,Ehrlich PF,Pritchard-Jones K.Wilms tumor: "state-of-the-art" update,2016[J].Semin Pediatr Surg,2016,25(5):250-256.DOI:10.1053/j.sempedsurg.2016.09.003.
[2] Venkatramani R,Malogolowkin MH,Mascarenhas L.Treatment of multiply relapsed Wilms tumor with vincristine,irinotecan,temozolomide and bevacizumab[J].Pediatr Blood Cancer,2014,61(4):756-759.DOI:10.1002/pbc.24785.
[3] 蒋鸿飞.肾母细胞瘤综合治疗研究进展[J].临床小儿外科杂志,2020,19(10):916-920.DOI:10.3969/j.issn.1671-6353.2020.10.010. Jiang HF.Research advances in the comprehensive treatments of Wilms’ tumor[J].J ClinPed Sur,2020,19(10):916-920.DOI:10.3969/j.issn.1671-6353.2020.10.010.
[4] 腹腔热灌注化疗技术临床应用专家协作组.腹腔热灌注化疗技术临床应用专家共识(2016版)[J].中华胃肠外科杂志,2016,9(2):121-125.DOI:10.3760/cma.j.issn.1671-0274.2016.02.001. Expert Collaboration Group on Clinical Application of Intraperitoneal Heat Perfusion Chemotherapy Technology: Expert Consensus on Clinical Application of Abdominal Heat Perfusion Chemotherapy Technology (2016 Edition)[J].Chin J GastrointestSurg,2016,19(2):121-125.DOI:10.3760/cma.j.issn.1671-0274.2016.02.001.
[5] Zmora O,Hayes-Jordan A,Nissan A,et al.Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for disseminated intra-abdominal malignancies in children-a single-institution experience[J].J PediatrSurg,2018,53(7):1381-1386.DOI:10.1016/j.jpedsurg.2017.09.014.
[6] Gesche J,Beckert S,Neunhoeffer F,et al.Cytoreductive surgery and hyperthermicintraperitoneal chemotherapy: a safe treatment option for intraperitonealrhabdomyosarcoma in children below 5 years of age[J].Pediatr Blood Cancer,2019,66(2):e27517.DOI:10.1002/pbc.27517.
[7] Brok J,Lopez-Yurda M,Tinteren HV,et al.Relapse of Wilms’ tumour and detection methods: a retrospective analysis of the 2001 renal tumour study group-international society of paediatric oncology Wilms’ tumour protocol database[J].Lancet Oncol,2018,19(8):1072-1081.DOI:10.1016/S1470-2045(18)30293-6.
[8] 洪博,董瑞.肾母细胞瘤治疗研究进展[J].临床小儿外科杂志,2021,20(6):569-575.DOI:10.12260/lcxewkzz.2021.06.012. Hong B,Dong R.Recent advances in the treatment of Wilms tumor[J].J Clin Ped Sur,2021,20(6):569-575.DOI:10.12260/lcxewkzz.2021.06.012.
[9] Groenendijk A,Spreafico F,de Krijger RR,et al.Prognostic factors for Wilms tumor recurrence: a review of the literature[J].Cancers (Basel),2021,13(13): 3142.DOI:10.3390/cancers13133142.
[10] Hol JA,Lopez-Yurda MI,Van Tinteren H,et al.Prognostic significance of age in 5631 patients with Wilmstumour prospectively registered in International Society of Paediatric Oncology (SIOP) 93-01 and 2001[J].PLoS One,2019,14(8): e0221373.DOI:10.1371/journal.pone.0221373.
[11] Spreafico F,Dalissier A,P?tschger U,et al.High dose chemotherapy and autologous hematopoietic cell transplantation for Wilms tumor: a study of the European Society for Blood and Marrow Transplantation[J].Bone Marrow Transplant,2020,55(2):376-383.DOI:10.1038/s41409-019-0661-7.
[12] Hayes-Jordan AA,Coakley BA,Green HL,et al.Desmoplastic small round cell tumor treated with cytoreductive surgery and hyperthermicintraperitoneal chemotherapy: results of a phase 2 trial[J].Ann Surg Oncol,2018,25(4):872-877.DOI:10.1245/s10434-018-6333-9.

Memo

收稿日期:2022-03-14。
通讯作者:王焕民,Email:wanghuanmin@bch.com.cn

Last Update: 1900-01-01